|
1
|
Sobin LH: Histological typing of thyroid
tumours. Histopathology. 16:5131990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bann DV, Goyal N, Camacho F and Goldenberg
D: Increasing incidence of thyroid cancer in the commonwealth of
pennsylvania. JAMA Otolaryngol Head Neck Surg. 140:1149–1156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burgess JR and Tucker P: Incidence trends
for papillary thyroid carcinoma and their correlation with thyroid
surgery and thyroid fine-needle aspirate cytology. Thyroid.
16:47–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
La Vecchia C, Malvezzi M, Bosetti C,
Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer
mortality and incidence: A global overview. Int J Cancer.
136:2187–2195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noguchi S, Yamashita H, Uchino S and
Watanabe S: Papillary microcarcinoma. World J Surg. 32:747–753.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qu H, Sun GR, Liu Y and He QS: Clinical
risk factors for central lymph node metastasis in papillary thyroid
carcinoma: A systematic review and meta-analysis. Clin Endocrinol
(Oxf). 83:124–132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo Y, Zhao Y, Chen K, Shen J, Shi J, Lu
S, Lei J, Li Z and Luo D: Clinical analysis of cervical lymph node
metastasis risk factors in patients with papillary thyroid
microcarcinoma. J Endocrinol Invest. Jun 6–2018.(Epub ahead of
print). doi: 10.1007/s40618-018-0908-y. View Article : Google Scholar
|
|
8
|
Frates MC, Benson CB, Doubilet PM,
Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen
PR, Marqusee E and Alexander EK: Prevalence and distribution of
carcinoma in patients with solitary and multiple thyroid nodules on
sonography. J Clin Endocrinol Metab. 91:3411–3417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marchetti I, Iervasi G, Mazzanti CM, Lessi
F, Tomei S, Naccarato AG, Aretini P, Alberti B, Di Coscio G and
Bevilacqua G: Detection of the BRAF(V600E) mutation in fine needle
aspiration cytology of thyroid papillary microcarcinoma cells
selected by manual macrodissection: An easy tool to improve the
preoperative diagnosis. Thyroid. 22:292–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoon JH, Kim EK, Kwak JY, Moon HJ and Kim
GR: Sonographic features and ultrasonography-guided fine-needle
aspiration of metastases to the thyroid gland. Ultrasonography.
33:40–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lew JI, Snyder RA, Sanchez YM and
Solorzano CC: Fine needle aspiration of the thyroid: Correlation
with final histopathology in a surgical series of 797 patients. J
Am Coll Surg. 213:188–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kiernan CM, Broome JT and Solórzano CC:
The Bethesda system for reporting thyroid cytopathology: A
single-center experience over 5 years. Ann Surg Oncol.
21:3522–3527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lynam-Lennon N, Maher SG and Reynolds JV:
The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos
Soc. 84:55–71. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sempere LF, Freemantle S, Pitha-Rowe I,
Moss E, Dmitrovsky E and Ambros V: Expression profiling of
mammalian microRNAs uncovers a subset of brain-expressed microRNAs
with possible roles in murine and human neuronal differentiation.
Genome Biol. 5:R132004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schwertheim S, Sheu SY, Worm K, Grabellus
F and Schmid KW: Analysis of deregulated miRNAs is helpful to
distinguish poorly differentiated thyroid carcinoma from papillary
thyroid carcinoma. Horm Metab Res. 41:475–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tetzlaff MT, Liu A, Xu X, Master SR,
Baldwin DA, Tobias JW, Livolsi VA and Baloch ZW: Differential
expression of miRNAs in papillary thyroid carcinoma compared to
multinodular goiter using formalin fixed paraffin embedded tissues.
Endocr Pathol. 18:163–173. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yip L, Kelly L, Shuai Y, Armstrong MJ,
Nikiforov YE, Carty SE and Nikiforova MN: MicroRNA signature
distinguishes the degree of aggressiveness of papillary thyroid
carcinoma. Ann Surg Oncol. 18:2035–2041. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nikiforova MN, Chiosea SI and Nikiforov
YE: MicroRNA expression profiles in thyroid tumors. Endocr Pathol.
20:85–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haugen BR: 2015 American thyroid
association management guidelines for adult patients with thyroid
nodules and differentiated thyroid cancer: What is new and what has
changed. Cancer. 123:372–381. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frates MC, Benson CB, Charboneau JW, Cibas
ES, Clark OH, Coleman BG, Cronan JJ, Doubilet PM, Evans DB,
Goellner JR, et al: Management of thyroid nodules detected at us:
Society of radiologists in ultrasound consensus conference
statement. Radiology. 237:794–800. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moon WJ, Jung SL, Lee JH, Na DG, Baek JH,
Lee YH, Kim J, Kim HS, Byun JS and Lee DH; and Thyroid Study Group,
Korean Society of Neuro- and Head and Neck Radiology, : Benign and
malignant thyroid nodules: US differentiation-multicenter
retrospective study. Radiology. 247:762–770. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The american thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi YJ, Baek JH, Baek SH, Shim WH, Lee
KD, Lee HS, Shong YK, Ha EJ and Lee JH: Web-based malignancy risk
estimation for thyroid nodules using ultrasonography
characteristics: Development and validation of a predictive model.
Thyroid. 25:1306–1312. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Borrelli N, Denaro M, Ugolini C, Poma AM,
Miccoli M, Vitti P, Miccoli P and Basolo F: miRNA expression
profiling of ‘noninvasive follicular thyroid neoplasms with
papillary-like nuclear features’ compared with adenomas and
infiltrative follicular variants of papillary thyroid carcinomas.
Mod Pathol. 30:39–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoruker EE, Terzioglu D, Teksoz S, Uslu
FE, Gezer U and Dalay N: MicroRNA expression profiles in papillary
thyroid carcinoma, benign thyroid nodules and healthy controls. J
Cancer. 7:803–809. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cong D, He M, Chen S, Liu X and Sun H:
Expression profiles of pivotal microRNAs and targets in thyroid
papillary carcinoma: An analysis of the cancer genome atlas. Onco
Targets Ther. 8:2271–2277. 2015.PubMed/NCBI
|
|
28
|
Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A,
Gundara JS, Ip JC, Glover A, Sywak MS, Delbridge LW, Robinson BG
and Sidhu SB: MicroRNA-222 and microRNA-146b are tissue and
circulating biomarkers of recurrent papillary thyroid cancer.
Cancer. 119:4358–4365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sondermann A, Andreghetto FM, Moulatlet
AC, da Silva Victor E, de Castro MG, Nunes FD, Brandão LG and
Severino P: miR-9 and miR-21 as prognostic biomarkers for
recurrence in papillary thyroid cancer. Clin Exp Metastasis.
32:521–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dettmer M, Perren A, Moch H, Komminoth P,
Nikiforov YE and Nikiforova MN: Comprehensive MicroRNA expression
profiling identifies novel markers in follicular variant of
papillary thyroid carcinoma. Thyroid. 23:1383–1389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chou CK, Chen RF, Chou FF, Chang HW, Chen
YJ, Lee YF, Yang KD, Cheng JT, Huang CC and Liu RT: miR-146b is
highly expressed in adult papillary thyroid carcinomas with high
risk features including extrathyroidal invasion and the BRAF(V600E)
mutation. Thyroid. 20:489–494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen YT, Kitabayashi N, Zhou XK, Fahey TJ
III and Scognamiglio T: MicroRNA analysis as a potential diagnostic
tool for papillary thyroid carcinoma. Mod Pathol. 21:1139–1146.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lawrie CH, Gal S, Dunlop HM, Pushkaran B,
Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J,
Wainscoat JS, et al: Detection of elevated levels of
tumour-associated microRNAs in serum of patients with diffuse large
B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang Z, Huang D, Ni S, Peng Z, Sheng W
and Du X: Plasma microRNAs are promising novel biomarkers for early
detection of colorectal cancer. Int J Cancer. 127:118–126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F,
Zhang Y, Huang K, Li Y, Song E, et al: Circulating microRNA
profiles as potential biomarkers for diagnosis of papillary thyroid
carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cibas ES and Ali SZ: The bethesda system
for reporting thyroid cytopathology. Thyroid. 19:1159–1165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cappelli C, Pirola I, Cumetti D,
Micheletti L, Tironi A, Gandossi E, Martino E, Cherubini L, Agosti
B, Castellano M, et al: Is the anteroposterior and transverse
diameter ratio of nonpalpable thyroid nodules a sonographic
criteria for recommending fine-needle aspiration cytology? Clin
Endocrinol (Oxf). 63:689–693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shivapurkar N, Weiner LM, Marshall JL,
Madhavan S, Mays Deslattes A, Juhl H and Wellstein A: Recurrence of
early stage colon cancer predicted by expression pattern of
circulating microRNAs. PLoS One. 9:e846862014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cui EH, Li HJ, Hua F, Wang B, Mao W, Feng
XR, Li JY and Wang X: Serum microRNA 125b as a diagnostic or
prognostic biomarker for advanced NSCLC patients receiving
cisplatin-based chemotherapy. Acta Pharmacol Sin. 34:309–313. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Selth LA, Townley SL, Bert AG, Stricker
PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM and Tilley WD:
Circulating microRNAs predict biochemical recurrence in prostate
cancer patients. Br J Cancer. 109:641–650. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li M, Song Q, Li H, Lou Y and Wang L:
Circulating miR-25-3p and miR-451a may be potential biomarkers for
the diagnosis of papillary thyroid carcinoma. PLoS One.
10:e01324032015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee YS, Lim YS, Lee JC, Wang SG, Park HY,
Kim SY and Lee BJ: Differential expression levels of plasma-derived
miR-146b and miR-155 in papillary thyroid cancer. Oral Oncol.
51:77–83. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cantara S, Pilli T, Sebastiani G, Cevenini
G, Busonero G, Cardinale S, Dotta F and Pacini F: Circulating
miRNA95 and miRNA190 are sensitive markers for the differential
diagnosis of thyroid nodules in a caucasian population. J Clin
Endocrinol Metab. 99:4190–4198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y, Xu D, Pan J, Yang Z, Chen M, Han
J, Zhang S, Sun L and Qiao H: Dynamic monitoring of circulating
microRNAs as a predictive biomarker for the diagnosis and
recurrence of papillary thyroid carcinoma. Oncol Lett.
13:4252–4266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim HY, Park WY, Lee KE, Park WS, Chung
YS, Cho SJ and Youn YK: Comparative analysis of gene expression
profiles of papillary thyroid microcarcinoma and papillary thyroid
carcinoma. J Cancer Res Ther. 6:452–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu R, Zhang C, Hu Z, Li G, Wang C, Yang
C, Huang D, Chen X, Zhang H, Zhuang R, et al: A five-microRNA
signature identified from genome-wide serum microRNA expression
profiling serves as a fingerprint for gastric cancer diagnosis. Eur
J Cancer. 47:784–791. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Giordano D, Gradoni P, Oretti G, Molina E
and Ferri T: Treatment and prognostic factors of papillary thyroid
microcarcinoma. Clin Otolaryngol. 35:118–124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mazzaferri EL: Management of low-risk
differentiated thyroid cancer. Endocr Pract. 13:498–512. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Q, Song F, Zheng H, Zhu X, Yao X,
Zhang L and Chen K: Association between single-nucleotide
polymorphisms of BRAF and papillary thyroid carcinoma in a chinese
population. Thyroid. 23:38–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Alzahrani AS and Xing M: Impact of lymph
node metastases identified on central neck dissection (CND) on the
recurrence of papillary thyroid cancer: Potential role of BRAFV600E
mutation in defining CND. Endocr Relat Cancer. 20:13–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang Y, Liao D, Pan L, Ye R, Li X, Wang
S, Ye C and Chen L: Expressions of miRNAs in papillary thyroid
carcinoma and their associations with the BRAFV600E mutation. Eur J
Endocrinol. 168:675–681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ
and Qu JM: The BRAF mutation is predictive of aggressive
clinicopathological characteristics in papillary thyroid
microcarcinoma. Ann Surg Oncol. 17:3294–3300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y,
Zhang Y, Cheng W and Zhao W: Analysis of differential BRAF(V600E)
mutational status in high aggressive papillary thyroid
microcarcinoma. Ann Surg Oncol. 16:240–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chow SM, Law SC, Chan JK, Au SK, Yau S and
Lau WH: Papillary microcarcinoma of the thyroid-prognostic
significance of lymph node metastasis and multifocality. Cancer.
98:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Niemeier LA, Akatsu Kuffner H, Song C,
Carty SE, Hodak SP, Yip L, Ferris RL, Tseng GC, Seethala RR, Lebeau
SO, et al: A combined molecular-pathologic score improves risk
stratification of thyroid papillary microcarcinoma. Cancer.
118:2069–2077. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ito Y, Miyauchi A, Inoue H, Fukushima M,
Kihara M, Higashiyama T, Tomoda C, Takamura Y, Kobayashi K and Miya
A: An observational trial for papillary thyroid microcarcinoma in
Japanese patients. World J Surg. 34:28–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lee CR, Park S, Kang SW, Lee J, Jeong JJ,
Nam KH, Chung WY and Park CS: Is familial papillary thyroid
microcarcinoma more aggressive than sporadic form. Ann Surg Treat
Res. 92:129–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guo Z, Hardin H, Montemayor-Garcia C,
Asioli S, Righi A, Maletta F, Sapino A and Lloyd RV: In situ
hybridization analysis of miR-146b-5p and miR-21 in thyroid
nodules: Diagnostic implications. Endocr Pathol. 26:157–163. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rosignolo F, Sponziello M, Giacomelli L,
Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina
L, Grani G, et al: Identification of thyroid-associated serum
microRNA profiles and their potential use in thyroid cancer
follow-up. J Endocr Soc. 1:3–13. 2017.PubMed/NCBI
|
|
64
|
Yusof Mohamad A, Jamal R, Muhammad R,
Suhaimi Abdullah SN, Rose Mohamed I, Saidin S and Mutalib Ab NS:
Integrated characterization of MicroRNA and mRNA transcriptome in
papillary thyroid carcinoma. Front Endocrinol (Lausanne).
9:1582018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang J, Liu Y, Liu Z, Wang XM, Yin DT,
Zheng LL, Zhang DY and Lu XB: Differential expression profiling and
functional analysis of microRNAs through stage I–III papillary
thyroid carcinoma. Int J Med Sci. 10:585–592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang Z, Zhang H, He L, Dong W, Li J, Shan
Z and Teng W: Association between the expression of four
upregulated miRNAs and extrathyroidal invasion in papillary thyroid
carcinoma. Onco Targets Ther. 6:281–287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Han PA, Kim HS, Cho S, Fazeli R, Najafian
A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, et al:
Association of braf V600E mutation and microRNA expression with
central lymph node metastases in papillary thyroid cancer: A
prospective study from four endocrine surgery centers. Thyroid.
26:532–542. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Dai L, Wang Y, Chen L, Zheng J, Li J and
Wu X: miR-221, a potential prognostic biomarker for recurrence in
papillary thyroid cancer. World J Surg Oncol. 15:112017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pallante P, Visone R, Croce CM and Fusco
A: Deregulation of microRNA expression in follicular-cell-derived
human thyroid carcinomas. Endocr Relat Cancer. 17:F91–F104. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Mardente S, Mari E, Consorti F, Di Gioia
C, Negri R, Etna M, Zicari A and Antonaci A: HMGB1 induces the
overexpression of miR-222 and miR-221 and increases growth and
motility in papillary thyroid cancer cells. Oncol Rep.
28:2285–2289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Shen J, Hruby GW, McKiernan JM, Gurvich I,
Lipsky MJ, Benson MC and Santella RM: Dysregulation of circulating
microRNAs and prediction of aggressive prostate cancer. Prostate.
72:1469–1477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yang L, Feng Y, Qi P, Xu S and Zhou Y:
Mechanism of serum miR-21 in the pathogenesis of familial and
triple negative breast cancer. J Biol Regul Homeost Agents.
30:1041–1045. 2016.PubMed/NCBI
|
|
73
|
He Y, Jin J, Wang L, Hu Y, Liang D, Yang
H, Liu Y and Shan B: Evaluation of miR-21 and miR-375 as prognostic
biomarkers in oesophageal cancer in high-risk areas in China. Clin
Exp Metastasis. 34:73–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Tang D, Shen Y, Wang M, Yang R, Wang Z,
Sui A, Jiao W and Wang Y: Identification of plasma microRNAs as
novel noninvasive biomarkers for early detection of lung cancer.
Eur J Cancer Prev. 22:540–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Oue N, Anami K, Schetter AJ, Moehler M,
Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, et
al: High miR-21 expression from FFPE tissues is associated with
poor survival and response to adjuvant chemotherapy in colon
cancer. Int J Cancer. 134:1926–1934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kjaer-Frifeldt S, Fredslund R, Lindebjerg
J, Hansen TF, Spindler KL and Jakobsen A; and Danish Colorectal
Cancer Group, : Prognostic importance of VEGF-A haplotype
combinations in a stage II colon cancer population.
Pharmacogenomics. 13:763–770. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xia X, Yang B, Zhai X, Liu X, Shen K, Wu Z
and Cai J: Prognostic role of microRNA-21 in colorectal cancer: A
meta-analysis. PLoS One. 8:e804262013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Guancial EA, Bellmunt J, Yeh S, Rosenberg
JE and Berman DM: The evolving understanding of microRNA in bladder
cancer. Urol Oncol. 32:41.e31–e40. 2014. View Article : Google Scholar
|
|
79
|
Terao M, Fratelli M, Kurosaki M, Zanetti
A, Guarnaccia V, Paroni G, Tsykin A, Lupi M, Gianni M, Goodall GJ
and Garattini E: Induction of miR-21 by retinoic acid in estrogen
receptor-positive breast carcinoma cells: Biological correlates and
molecular targets. J Biol Chem. 286:4027–4042. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Buitrago D, Keutgen XM, Crowley M,
Filicori F, Aldailami H, Hoda R, Liu YF, Hoda RS, Scognamiglio T,
Jin M, et al: Intercellular adhesion molecule-1 (ICAM-1) is
upregulated in aggressive papillary thyroid carcinoma. Ann Surg
Oncol. 19:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K
and Yang GH: MicroRNA-21 (miR-21) represses tumor suppressor PTEN
and promotes growth and invasion in non-small cell lung cancer
(NSCLC). Clin Chim Acta. 411:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lv C, Hao Y and Tu G: MicroRNA-21 promotes
proliferation, invasion and suppresses apoptosis in human
osteosarcoma line MG63 through PTEN/Akt pathway. Tumour Biol.
37:9333–9342. 2016. View Article : Google Scholar : PubMed/NCBI
|
